{'fraction_non_alphanumeric': 0.04044117647058824, 'fraction_numerical': 0.025735294117647058, 'mean_word_length': 5.640243902439025, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Use of the platelet function analyser (PFA‐100®) to quantify the effect of low dose aspirin in patients with ischaemic heart disease

Continuing aspirin up until surgery in cardiac surgical patients may increase peri‐operative blood loss. It is possible that there is a subset of patients particularly sensitive to aspirin. The platelet function analyser (PFA‐100®) can demonstrate the antiplatelet effect of aspirin. This study was designed to assess the effect of daily 75 mg aspirin on platelet function, as measured by the PFA‐100®, in 92 patients with ischaemic heart disease. Patients were classified into three groups according to their PFA‐100® results; aspirin hyper‐responders (16%), aspirin normal responders (33%) and aspirin non‐responders (51%). The PFA‐100® has potential as a screening tool to identify patients who are either hyper‐responsive or resistant to aspirin. Pre‐operative PFA‐100® screening to isolate aspirin hyper‐responders could enable the vast majority of patients to continue with aspirin therapy pre‐operatively, avoiding the risks of stopping treatment.